We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
On July 24, Nabriva Therapeutics announced the acquisition of Zavante Therapeutics, a biotechnology company developing treatments for the infections that threaten hospitalized patients.